Showing 5281-5290 of 7383 results for "".
- Study Highlights Skin Cancer Disparities in Hispanic/Latino Patientshttps://practicaldermatology.com/news/study-highlights-skin-cancer-disparities-in-hispaniclatino-patients/2460950/When Hispanic/Latino people are diagnosed with skin cancer, their tumors are 17 percent larger than tumors in non-Hispanic White patients, a new study shows. For the study, researchers analyzed a total of 3,486 Mohs micrographic surgeries of basal cell, squamous cell, and bas
- Aveeno Launches #SkinVisibility Campaignhttps://practicaldermatology.com/news/aveeno-launches-skinvisibility-campaign/2460948/Aveeno’s new #SkinVisibility campaign aims to address the underdiagnosis, care and treatment of eczema on Black skin. The campaign, which launches during Eczema Awareness Month, underscores the brand's pledge to help 100,000 people with eczema find relief&n
- Safety Concerns Fuel Vaccine Hesitancy in PsO Patients on Biologics, But Data Fail to Show Increased Riskhttps://practicaldermatology.com/news/safety-concerns-fuel-vaccine-hesitancy-in-pso-patients-on-biologics-but-data-fail-to-show-increased-risk/2460947/Safety concerns and concerns about aggravation of their underlying condition are common drivers of COVID-19 vaccine hesitancy among patients with psoriatic disease, results of a new study show. Data come from an analysis of social media posts from patients in the US, UK, France, Germany, and
- Topline Phase 2b Data Promising for Timber's Topical Isotretinoin in CIhttps://practicaldermatology.com/news/topline-phase-2b-data-promising-for-timbers-topical-isotretinoin-in-ci/2460946/Top-line data from Timber Pharmaceuticals’ Phase 2b CONTROL study show “clinically meaningful efficacy with a favorable safety profile” for investigational topical isotretinoin, says the company’s Chairman and CEO John Koconis. TMB-001 is formulated using
- Experts Highlight Need to Focus on Psoriasis Patients’ Wellbeing in Practicehttps://practicaldermatology.com/news/experts-highlight-need-to-focus-on-psoriasis-patients-wellbeing-in-practice/2460945/In addition to managing the clinical manifestations of psoriasis, clinical practices should implement an overall and holistic assessment of the wellbeing of each patient, says a panel of scientists speaking at a symposium during the European Association of Dermatology and Venereology (EADV) 30th&
- Amgen/Kyowa Kirin's Anti-OX40 Shows Efficacy in Phase 2 for ADhttps://practicaldermatology.com/news/amgenkyowa-kirins-anti-ox40-shows-efficacy-in-phase-2-for-ad/2460943/Positive data from a Phase 2 study of AMG 451/KHK4083, presented at the European Academy of Dermatology and Venereology 30th Virtual Congress, show that the potential first-in-class anti-OX40 fully human monoclonal antibody in development for the treatment of moderate-to-severe atopic d
- Updates from EADV: Cosentyx Autoinjector, Genetic Variants Linked to Genital Warts, At-Home PDT Shows Promisehttps://practicaldermatology.com/news/updates-from-eadv-cosentyx-autoinjector-genetic-variants-linked-to-genital-warts-at-home-pdt-shows-promise/2460939/• Treatment with Cosentyx®(secukinumab) 300mg in a 2mL autoinjector (UnoReady® pen) was more effective than placebo and achieved high patient satisfaction compared to two 150mg pre-filled syringes, according to Phase 3b data presented
- Investigational Agents Show Benefit in Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/investigational-agents-show-benefit-in-chronic-spontaneous-urticaria/2460938/Complete control of chronic spontaneous urticaria (CSU) is associated with improvements in key HRQoL measures, such as overall quality of life, sleep interference, activity interference and work impairment, while a marked decline in these improvements to quality of life is seen among patients wit
- New Data for Galderma’s Nemolizumab Show Rapid Onset in Prurigo Nodularis and Atopic Dermatitishttps://practicaldermatology.com/news/new-data-for-galdermas-nemolizumab-show-rapid-onset-in-prurigo-nodularis-and-atopic-dermatitis/2460935/Investigational monoclonal antibody nemolizumab demonstrates rapid onset of action and significant reduction in symptoms for patients with prurigo nodularis (PN) and atopic dermatitis (AD), according to data presented at the virtual 30th EADV congress and reported by
- Data Show Continuous Response to LEO's Tralokinumab in Adults with ADhttps://practicaldermatology.com/news/data-show-continuous-response-to-leos-tralokinumab-in-adults-with-ad/2460933/After two years of continuous treatment with tralokinumab, adult patients with moderate-to-severe atopic dermatitis maintained improvements in signs and symptoms, itch severity, and sleep interference, according to interim findings from the Phase 3 ECZTEND trial presented as an oral presenta